1.09
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
CGTLive®’s Weekly Rewind – July 25, 2025 - CGTLive®
Ocugen Inc. Stock Analysis and ForecastFree Risk Assessment Services - PrintWeekIndia
What analysts say about Ocugen Inc. stockMarket-leading profit generation - Autocar Professional
What risks could impact Ocugen Inc. stock performanceRapidly growing investment returns - jammulinksnews.com
What drives Ocugen Inc. stock priceStrongest growth potential - Autocar Professional
When is the best time to buy Ocugen Inc. stockMarket-leading growth rates - jammulinksnews.com
First Patient Dosed in Phase 2/3 GARDian3 Trial of OCU410ST for Stargardt Disease - CGTLive®
Is Ocugen Inc. a good long term investmentSkyrocketing profit margins - jammulinksnews.com
Ocugen, Inc. Announces New Appointments to its Retina Scientific Advisory Board and Executive Leadership Team - VisionMonday.com
Ocugen announces appointments to retina scientific advisory board and executive leadership team - Ophthalmology Times
Ocugen Bets Big On Gene Therapy Despite Major Setbacks - Finimize
Ocugen, Inc. Announces New Appointments to Retina Scientific Adv - GuruFocus
Ocugen expands advisory board and leadership team for gene therapy push - Investing.com India
Ocugen, Inc. Strengthens Retina Scientific Advisory Board and Leadership Team to Advance Gene Therapy Development for Blindness Diseases - Quiver Quantitative
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team - GlobeNewswire
Ocugen Assembles Elite Gene Therapy Team: 3 Top Retina Experts Join as Company Targets Triple BLA Filing - Stock Titan
Ocugen doses first subject in trial of modifier gene therapy candidate - Yahoo Finance
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy - MyChesCo
Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN
Ocugen’s Phase 1 Study on OCU200: A Potential Game-Changer for Diabetic Macular Edema - TipRanks
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 - GuruFocus
Ocugen doses first patient in phase 2/3 Stargardt disease trial - Investing.com Australia
Ocugen doses first patient in phase 2/3 Stargardt disease trial By Investing.com - Investing.com South Africa
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 - GlobeNewswire
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):